Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EMN 2018 | ASCT remains at the forefront of multiple myeloma therapy

Despite recent advances in drug development, autologous stem cell transplant (ASCT) is still, to date, the most effective treatment for multiple myeloma (MM). Speaking from the 1st European Myeloma Network Meeting (EMN) in Turin, Italy, Vittorio Montefusco, MD, of the IRCCS Foundation, National Cancer Institute of Milan, Milan, Italy, explains why this is the case. Dr Montefusco outlines the benefits of using drugs in combination with ASCT, and highlights how the difference in patient fitness between older and younger populations can influence the course of treatment.